Showing 1301-1310 of 7668 results for "".
- Precision Medicine in Action: Clinical Features May Help ID High Risk Melanoma Patientshttps://practicaldermatology.com/news/precision-medicine-in-action-clinical-featires-may-help-id-high-risk-melanoma-patients/2458379/Zeroing in on an individual’s risk factors for melanoma can help identify high-risk patients who may benefit from increased surveillance, new research suggests. Caroline G. Watts, M.P.H., of the University of Sydney, Australia, and coauthors examined clinical features associated with melanomas acc…
- Most Indoor Tanning Salons in Texas Do Comply with Tanning Bans for Minorshttps://practicaldermatology.com/news/most-indoor-tanning-salons-in-texas-do-comply-with-tanning-bans-for-minors/2458378/Most indoor tanning salons comply with Texas’ tanning ban for those under 18, new research suggests. When female employees of a mystery shopping firm called posing as 17-year-olds interested in tanning, 81 percent of indoor tanning facilities complied with the Texas ban on indoor tanning for those…
- FDA Approves Expanded Use Of Enbrel To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-expanded-use-of-enbrel-to-treat-children-with-chronic-moderate-to-severe-plaque-psoriasis/2458383/The FDA has approved the supplemental Biologics License Application (sBLA) for the expanded use of Amgen's Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. The approval is based on results f…
- Can IL-33 Blockade Ease Severe Poison Ivy Itch? Mouse Study Says Maybehttps://practicaldermatology.com/news/can-il-33-blockers-ease-severe-poison-ivy-itch/2458382/Blocking interleukin 33 (IL-33) may put the brakes on the uncontrollable itch caused by poison ivy, poison sumac, poison oak and even mango trees, according to a mouse study conducted by scientists at Duke Health in Durham, NC, and Zhejiang Chinese Medical University in China. The research appear…
- New From Dr. Macrene 37 Actives: High Performance Anti-Aging and Filler Lip Treatmenthttps://practicaldermatology.com/news/new-from-dr-macrene-37-actives-high-performance-anti-aging-and-filler-lip-treatment/2458388/Dr. Macrene 37 Actives is rolling out a new needle-free anti-aging lip filler. 37 Actives High Performance Anti-Aging and Filler Lip Treatment is formulated with more than 20 anti-aging actives including high concentrations of hyaluronic acid and peptides to fight the appearance of wrinkles while …
- The Election and The Marketshttps://practicaldermatology.com/news/the-election-and-the-markets/2458392/By David Mandell, JD, MBA and Robert Peelman, CFP® This presidential race is seemingly generating more interest, expressions of concern, and questions from clients than past elections. Some clients want to know how the election impacts our investment views and how we might adjust our positioning i…
- FDA Clears Merz Aesthetics' Cellfina System for Long-Term Improvement of Cellulitehttps://practicaldermatology.com/news/fda-clears-merz-aesthetics-cellfina-system-for-long-term-improvement-of-cellulite/2458399/The FDA has cleared the Cellfina System from Merz Aesthetics, a division of Merz North America, for the long-term improvement in the appearance of cellulite on the buttocks and thighs of adult females with no loss of benefit for up to 3 years. Cellfina is the only FDA-cleared minimally invasive pr…
- Sweden Greenlights Allergan's Double Chin-Melting BELKYRA®https://practicaldermatology.com/news/sweden-greenlights-allergans-double-chin-melting-belkyra/2458404/The Swedish Medical Products Agency has greenlighted Allergan’s BELKYRA® (deoxycholic acid) for submental fat reduction. BELKYRA® is already licensed in Canada, Australia, Iceland, Hungary, Austria, Lithuania, Estonia, Latvia, Romania, Bulgaria and Norway, as well as in the U.S. as KYBELLA. Sweden…
- Opdivo Stabilized Patient-reported Outcomes in Previously Treated Recurrent or Metastatic SCC of Head and Neckhttps://practicaldermatology.com/news/opdivo-stabilized-patient-reported-outcomes-in-previously-treated-recurrent-or-metastatic-scc-of-head-and-neck/2458409/Bristol-Myers Squibb Company reported new patient-reported quality-of-life data from an exploratory endpoint in the pivotal Phase 3 CheckMate -141 trial evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after platinum therapy compared to investi…
- Phase 3 Study: Yervoy Improves Overall Survival in Fully Resected Stage III Melanoma Patientshttps://practicaldermatology.com/news/phase-3-study-yervoy-improves-overall-survival-in-fully-resected-stage-iii-melanoma-patients/2458408/Yervoy 10 mg/kg demonstrated superiority versus placebo on all survival endpoints in the Phase 3 trial CA184-029 (EORTC 18071) evaluating stage III melanoma patients who are at high risk of recurrence following complete surgical resection, according to Bristol-Myers Squibb Company. In the study, Ye…